SCHEMBL1809784

SCHEMBL1809784

CCOC(=O)Cc1csc(SCC(=O)NCC2CN(Cc3ccc(F)c(F)c3)CCO2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.47
ALDH1A1 P00352 6/20 0.44
ALOX15 P16050 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
POLB P06746 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
DRD4 P21917 2/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
MCHR1 Q99705 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1809786 1.00 HPGD (0.47) HPGDALDH1A1ALOX15MEN1KMT2A
SCHEMBL1813488 0.94 HPGD (0.46) HPGDALDH1A1ALOX15MEN1KMT2A
SCHEMBL1813489 0.94 HPGD (0.46) HPGDALDH1A1ALOX15MEN1KMT2A
SCHEMBL1807387 0.94 HPGD (0.45) HPGDALDH1A1ALOX15MEN1KMT2A
SCHEMBL1807385 0.94 HPGD (0.45) HPGDALDH1A1ALOX15MEN1KMT2A
SCHEMBL1811189 0.93 HPGD (0.48) HPGDALDH1A1ALOX15MEN1KMT2A
SCHEMBL1811191 0.93 HPGD (0.48) HPGDALDH1A1ALOX15MEN1KMT2A
SCHEMBL1810568 0.93 DRD4 (0.45) HPGDALDH1A1ALOX15MEN1KMT2A
SCHEMBL1810569 0.93 DRD4 (0.45) HPGDALDH1A1ALOX15MEN1KMT2A
SCHEMBL1810458 0.92 HPGD (0.49) HPGDALDH1A1ALOX15MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 HPGD 3730/4885ALDH1A1 2661/4885ALOX15 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.